求问、关于birinapant

战天斗hbv

为什么Google上没有任何关于birinapant治疗hbv的文献？为什么？我感觉很蹊跷、别的药物在临床前、多少都有些相关文献资料的、一般都是阐述了前期概念后、才做的药物、但是birinapant没有、有的只是它关于癌症的、那么、到底是谁发现的birinapant对hbv有效、此人也不发个论文啥的、太奇怪了、求解答、我认为如果我发现birinapant在实验室阶段对hbv有效、我肯定搞个论文、影响因子杠杠的,有这么高影响因子文章的发布、我就什么都有了、你懂得、所以、为什么呢？没有前期研究的文章？很是奇怪

战天斗hbv

一句话、我怕失望、怕birinapant失败反过来说、如果成功、定是根除！
不怕笑话、我对birinapant唯一的不满、就是不是口服药物

qazwsx1234

回复 战天斗hbv 的帖子

https://respond.niaid.nih.gov/conferences/ogrconference2015/Documents/Hepatitis%20Panel%20Abstracts.pdf?Mobile=1

qazwsx1234

回复 qazwsx1234 的帖子

我觉得美国圣路易斯大学的Dr. John Tavis博士的RNAH酶抑制剂思路我觉得还好，我觉得你可以去查查他的文章

qazwsx1234

回复 战天斗hbv 的帖子

我觉得美国圣路易斯大学的Dr. John Tavis博士的RNAH酶抑制剂思路我觉得还好，我觉得你可以去查查他的文章

战天斗hbv

第一、你没有回答我的问题、有点歪楼
第二、你有好东西、可以分享给大家、没必要你我独享、众人均享、岂不美哉、我觉得这也是本版的精神、sw、ncb完全可以自己看看文献就完了第三、东西不错、可以单开一帖、贴在这、有些朋友可能看不见

战天斗hbv

New animal models for studying persistent hepatitis virus infections
Hepatotropic infections including hepatitis B (HBV) and C viruses (HCV) infect over 600 million people
worldwide and are major causative agents of liver disease including fibrosis, cirrhosis and liver cancer.
Development of more effective clinical therapies has been delayed by the lack of robust and suitable
animal models. Both HBV and HCV have an almost unique and mechanistically unexplained host tropism
limited to robust infections in humans and chimpanzees. We are pursuing three independent but
possibly complementary approaches to overcome current species barriers and generate a small animal
model for persistent HBV and HCV: 1. Adaptation of HCV and HBV genomes to infect hepatocytes of
non-human primates, with the long-term goal of a simian tropic HCV and HBV strains. 2. Humanization
of the mouse liver and immune system by transplanting human hematopoietic stem cells and
hepatocytes into a single murine recipient, thus allowing studies of pathology, immune correlates, and
mechanisms of HBV and HCV persistence. 3. Genetic host adaptation to create an inbred murine model
for HBV and HCV. Through the development and use of these platforms, we aim to shed light on HBV
and HCV molecular virology, to understand the associated liver disease, and to uncover novel avenues
for therapeutic intervention

战天斗hbv

Modeling human liver development, chronic hepatitis B virus infection, immunopathogenesis and
therapy in humanized mice
MT Bility1, F Li1, L Cheng1, C. Murphy1, Kouki Nio1, L Zhang2, and Lishan Su1, 2
1Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, School of Medicine, The University
of North Carolina at Chapel Hill, NC 27599, USA; 2Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
Background: Chronic hepatitis B infection affects over 350 million individuals resulting in chronic liver
inflammation, cirrhosis and hepatocellular carcinoma. The mechanisms of chronic HBV infection and
immunopathogenesis are poorly understood, and its therapeutic option is limited, due to a lack of
relevant robust animal models.
Materials: We have recently developed novel humanized mouse models with both human immune
system and human liver cells by reconstituting highly immunodeficient mice with human hematopoietic
stem cells and liver progenitor cells (NBT-hu HSC/Hep mice). The NBT-hu HSC/Hep mouse supports
persistent HBV and HCV infection.
Results: We detect human immune responses to HBV in the spleen/LN but they are impaired in the liver.
Furthermore, we detect human liver-specific chronic liver inflammation and fibrosis/cirrhosis in the
infected humanized mice. Analysis of chronic HBV/HCV-induced liver inflammation showed high level of
infiltrated human macrophages with M2-like phenotypes. Additionally, HBV/HCV-induced M2-like
macrophages were associated with Th1 impairment and tissue fibrosis in infected animals. Importantly,
similar M2-like macrophage accumulation was confirmed in chronic hepatitis virus infected patients
with liver diseases. Furthermore, we demonstrate that HBV/HCV preferentially induced M2-related
genes in both M1 and M2 macrophages. Finally, HBV infection and its associated immunopathogenesis
were prevented by treatment with a novel anti-HBV neutralizing antibody or by modulating host
immune responses.
Conclusions: Our study demonstrates that humanized mice with both human immune and liver cells
provide a valuable in vivo platform for studying HBV infection, human immune
responses/immunopathogenesis and associated liver diseases, as well as for developing novel
therapeutics targeting viral and host factors.

战天斗hbv

模型的建立、我认为、是更重要的一环、是药物研发的基石

战天斗hbv

顶顶、有人能回答我的问题吗